NAMENDA XR® (memantine hydrochloride) extended-release
capsules are indicated for the treatment of moderate to severe dementia of the Alzheimer’s type.
Important Safety Information
NAMENDA XR is contraindicated in patients with known hypersensitivity to memantine hydrochloride
or to any excipients used in the formulation.
Warnings and Precautions
Conditions that raise urine pH may decrease the urinary elimination of memantine resulting in increased plasma
levels of memantine.
The most commonly observed adverse reactions in patients administered NAMENDA XR (28 mg/day) in a
controlled clinical trial, defined as those occurring at a frequency of at least 5% in the NAMENDA
XR group and at a higher frequency than placebo were headache (6% vs 5%), diarrhea (5% vs 4%),
and dizziness (5% vs 1%).
NAMENDA XR has not been systematically evaluated in patients with a seizure disorder.
Alterations of urine pH toward the alkaline condition may lead to an accumulation of memantine with a possible
increase in adverse reactions. NAMENDA XR should be used with caution under conditions that may be associated
with increased urine pH including alterations by diet, drugs, and the clinical state of the patient.
No drug-drug interaction studies have been conducted with NAMENDA XR, specifically. The combined use
of NAMENDA XR with other NMDA antagonists (amantadine, ketamine, or dextromethorphan) has not been
systematically evaluated and such use should be approached with caution.
Dosage and Administration
The recommended starting dose of NAMENDA XR is 7 mg once daily. The recommended target dose is 28 mg once
daily. The dose should be increased in 7 mg increments to 28 mg once daily. The minimum recommended interval
between dose increases is one week, and only if the previous dose has been well tolerated. The maximum recommended
dose is 28 mg once daily.
It is recommended that a patient who is on a regimen of 10 mg twice daily of NAMENDA tablets be switched to NAMENDA
XR 28 mg once-daily capsules the day following the last dose of a 10 mg NAMENDA tablet. There is no study addressing
the comparative efficacy of these 2 regimens.
It is recommended that a patient with severe renal impairment who is on a regimen of 5 mg twice daily of NAMENDA
tablets be switched to NAMENDA XR 14 mg once-daily capsules the day following the last dose of a 5 mg NAMENDA tablet.
NAMENDA XR should be administered with caution to patients with severe hepatic impairment.
A target dose of 14 mg/day is recommended in patients with severe renal impairment (creatinine clearance of 5-29 mL/min,
based on the Cockcroft-Gault equation).
Please see full